Just a few years ago, Immunocore looked like another UK biotech destined not to live up to the promise of its science and early investor enthusiasm.
The company raised $320m in a series A in 2015 to develop its innovative T-cell receptor (TCR) immunotherapy platform, at...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?